BUY
₹1,829
₹1,788
₹2,111
15.42%
Geojit Investments Limited retained its BUY rating on Aurobindo Pharma Ltd. in its November 16, 2026 Q2FY27 result update and revised its target price to Rs 2,111.
The broker’s positive view reflects broad-based momentum in core formulations, growth in key geographies, progress in differentiated businesses and potential medium-term growth from biosimilars, biologics contract manufacturing and Contract Development and Manufacturing Organisation initiatives.
Aurobindo Pharma reported record consolidated revenue of Rs 10,263 crore in Q2FY27, up 23.9 per cent YoY and 12.2 per cent QoQ. Growth was supported by formulations and active pharmaceutical ingredients, consolidation of Lannett Company LLC, strong injectables momentum and differentiated product launches.
| Metric | Q2FY27 | Growth |
|---|---|---|
| US formulations revenue | Rs 4,555 crore | 25.2 per cent YoY |
| Europe revenue | Rs 3,161 crore | 27.5 per cent YoY |
| EBITDA | Rs 2,156 crore | 28.5 per cent YoY; 14.6 per cent QoQ |
| EBITDA margin | 21.0 per cent | Up 70 basis points YoY and 40 basis points QoQ |
| Adjusted PAT | Rs 1,126 crore | 32.8 per cent YoY |
| Adjusted EPS | Rs 19.6 | 34.0 per cent YoY |
US formulations revenue increased 25.2 per cent YoY to Rs 4,555 crore, aided by Lannett integration, volume expansion and the ramp-up of injectables. Europe revenue grew 27.5 per cent YoY to Rs 3,161 crore on robust execution, portfolio expansion and improved supply-chain support.
Geojit attributed the margin improvement to scale benefits, a stronger product mix, manufacturing efficiencies and improving operating leverage. For H1FY27, revenue grew 20.2 per cent YoY to Rs 19,414 crore, EBITDA increased 23.0 per cent to Rs 4,037 crore and adjusted PAT rose 31.5 per cent to Rs 2,199 crore.
Management reiterated FY27 guidance for double-digit revenue growth, EBITDA margin above 21 per cent and EBITDA exceeding Rs 8,000 crore.
Geojit increased its FY27E and FY28E estimates after the quarterly performance.
| Metric | FY27E | FY28E |
|---|---|---|
| Revenue | Rs 40,028 crore, raised 6.3 per cent | Rs 44,826 crore, raised 10.1 per cent |
| EBITDA | Rs 8,582 crore, raised 9.9 per cent | Rs 9,764 crore, raised 12.9 per cent |
| EBITDA margin | 21.4 per cent | 21.8 per cent |
The broker expects EBITDA margin to expand from 20.4 per cent in FY26A to 21.4 per cent in FY27E and 21.8 per cent in FY28E. Its target price is based on 22 times FY28E adjusted EPS.
Further regulatory action at the Lannett facility remains the key monitorable risk to the investment thesis.
Disclaimer: This is a summary of a research report published by the broker/research house identified above. The views, recommendations, target prices and estimates are those of the respective broker and do not represent DSIJ investment advice. The summary may be AI-assisted, hence please refer to the original report for complete details, disclosures and risks.
Copyright 2026 by DSIJ Wealth Advisory Pvt. Ltd. (Formerly Known as DSIJ Pvt. Ltd.)